Copperwynd Financial, LLC Abb Vie Inc. Transaction History

Copperwynd Financial, LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 15, 2024	BUY	$154.79 - $180.76 $55,105 - $64,350	356 Added 29.52%	1,562 $267,000
Q1 2024 Apr 30, 2024	SELL	$159.82 - $182.1 $85,503 - $97,423	-535 Reduced 30.73%	1,206 $219,000
Q4 2023 Feb 13, 2024	BUY	$137.6 - $154.97 $7,292 - $8,213	53 Added 3.14%	1,741 $269,000
Q3 2023 Nov 07, 2023	BUY	$133.59 - $154.65 $400 - $463	3 Added 0.18%	1,688 $251,000
Q2 2023 Aug 08, 2023	SELL	$132.51 - $164.9 $1.28 Million - $1.6 Million	-9,697 Reduced 85.2%	1,685 $227,000
Q1 2023 Apr 28, 2023	BUY	$144.61 - $166.54 $198,115 - $228,159	1,370 Added 13.68%	11,382 $1.81 Million
Q4 2022 Feb 02, 2023	BUY	$138.31 - $165.87 $19,086 - $22,890	138 Added 1.4%	10,012 $1.62 Million
Q3 2022 Nov 10, 2022	SELL	$134.21 - $153.93 $18,520 - $21,242	-138 Reduced 1.38%	9,874 $1.33 Million
Q2 2022 Aug 05, 2022	SELL	$137.62 - $174.96 $1.96 Million - $2.49 Million	-14,256 Reduced 58.74%	10,012 $1.53 Million
Q1 2022 Apr 21, 2022	BUY	$131.98 - $163.75 $3.2 Million - $3.97 Million	24,268 New	24,268 $3.93 Million

3,808

1.27B

13M

9.94M

Ticker ABBV
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,768,099,968
Market Cap $301B
Description
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...

Get notified when there are updates to the investment portfolio of Copperwynd Financial, LLC, based on Form 13F filings with the SEC.

Stay updated on Copperwynd Financial, LLC with notifications on news.